Men diagnosed with high-risk localized prostate cancer now have trial-level evidence that adding the drug apalutamide to ...

Androgen deprivation therapy (ADT), also called hormone therapy, is a common treatment for metastatic prostate cancer. It works by starving the cancer of testosterone, which fuels the tumor’s growth.

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

Two types of androgen deprivation therapy (ADT) had different effects on coronary atherosclerosis in a small randomized trial of men with prostate cancer. Significantly more coronary artery plaque ...

In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...

Metformin did not prevent development of metabolic syndrome in men receiving androgen deprivation therapy for prostate cancer in a phase III trial. Metformin was associated with improvement in weight, ...

A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...

Men taking androgen deprivation therapy (ADT) for prostate cancer were almost twice as likely to be diagnosed with Alzheimer's disease in the years that followed than those who didn't undergo the ...

Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.